QCG
AVBP icon

Quadrant Capital Group’s ArriVent BioPharma AVBP Stock Holding History

Quadrant Capital Group’s Portfolio AVBP Stock Details AVBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-21
Closed -$560 – 2851
2024
Q4 		$560 Buy
+21
New +$603 ﹤0.01% 2643

Other funds holding AVBP

HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
IAM
Infinitum Asset Management Fort Lauderdale, Florida $801M AUM 8.83% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Quadrant Capital Group's AVBP Position: Q1 2025 in Review

Quadrant Capital Group sold out of ArriVent BioPharma (AVBP) in Q1 2025, closing a stake of 21 shares — an estimated $560 sold.

Quadrant Capital Group first reported a position in AVBP in Q4 2024 and held it in 1 quarter. The position peaked at $560 in Q4 2024. 83 funds tracked by Wall St. Rank hold AVBP as of Q1 2025.

  • Quadrant Capital Group reported no remaining ArriVent BioPharma position as of Q1 2025 after selling out during the quarter.
  • Quadrant Capital Group sold 21 ArriVent BioPharma shares in Q1 2025, an estimated $560.
  • Quadrant Capital Group first reported a position in ArriVent BioPharma in Q4 2024 and held it in 1 quarter.
  • Quadrant Capital Group's ArriVent BioPharma position peaked at $560 in Q4 2024.
  • 83 funds tracked by Wall St. Rank held ArriVent BioPharma as of Q1 2025.

Based on Quadrant Capital Group's 13F filing for Q1 2025, filed 13 May 2025.